# Claude Science, the tool that could accelerate Western scientific research > On June 30, 2026, Anthropic unveiled Claude Science, a workspace designed to transform how researchers conduct their daily work. Far from being - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-05 - Canonical URL: https://mad-max.co/en/article/claude-science-l-outil-qui-pourrait-accelerer-la-recherche-scientifique-occident ## Introduction: when artificial intelligence walks into the lab ### A launch that goes beyond a simple tech gadget On June 30, 2026, **Anthropic** unveiled **Claude Science**, a workspace designed to transform how researchers conduct their daily work. Far from being just an upgraded chatbot, this tool integrates more than **60 recognized scientific databases** such as **UniProt**, **PDB**, **Ensembl**, and **ChEMBL**, in a single environment where scientists can analyze the literature, run complex analyses, and produce publication-ready figures. This announcement is part of a broader **technology race** in which major Western **artificial intelligence** companies are seeking to demonstrate concrete usefulness beyond entertainment or office productivity, by tackling **scientific discovery processes** themselves head-on. ### Why this launch deserves the public's attention Contrary to popular belief, this is not a new, more powerful artificial intelligence model. **Anthropic** has been explicit: **Claude Science** runs on existing models, including **Claude Opus 4.8**, with no special access or hidden extra capability. The innovation instead lies in the architecture of the software harness surrounding the model. This technical distinction is crucial to understanding the true scope of the announcement: it is not a breakthrough in **raw intelligence**, but a breakthrough in **workflow engineering**, which could paradoxically have a more immediate impact on actual **scientific productivity**. *I find it fascinating that this decade's real innovation is not always the most powerful model, but how intelligently it gets woven into concrete workflows. Anthropic may have just grasped something its competitors underestimated.* ## How Claude Science actually works ### A coordinating agent that delegates to specialized sub-agents The architecture of **Claude Science** rests on a generalist **coordinating agent** that acts like a virtual project manager. This agent can spin up **specialized sub-agents** to divide the work, much like a research director delegating specific tasks to team members based on their expertise. This **modular approach** allows several aspects of a complex research project to be handled simultaneously, whether in **genomics**, **proteomics**, **structural biology**, or **computational chemistry**, without the researcher having to manually juggle dozens of disparate tools. ### A reviewer agent to limit errors and hallucinations A notable and reassuring fact for the scientific community: **Anthropic** has built in a **separate reviewer agent** tasked with checking citations and calculations before anything is incorporated into a manuscript intended for publication. Every result produced keeps a complete **auditable history**, including the **source code** used and the execution environment. This verification function directly addresses one of the biggest fears surrounding the use of **artificial intelligence** in research: the proliferation of **fabricated citations** or **erroneous calculations** that could contaminate the scientific literature if not caught in time. *I welcome this methodological caution, but I stay clear-eyed: a reviewer agent built on the same underlying model as the agent it checks is not an absolute guarantee of independence. It is real progress, not a perfect solution, and that needs to be said plainly.* ## Anthropic's pharmaceutical ambition takes shape ### An internal drug discovery program for neglected diseases Alongside the launch of **Claude Science**, **Anthropic** announced its own **drug discovery program**, led by **Eric Kauderer-Abrams**, the company's head of life sciences. This program specifically targets **neglected diseases**, the ones traditional pharmaceutical industry often abandons for lack of sufficient commercial profitability. This strategic decision positions **Anthropic** not only as a tool provider for the **pharmaceutical industry**, but as a **direct player** in **medical research**, a significant **shift in posture** for an artificial intelligence company. ### A spectacular demonstration at launch During the launch demonstration, **Claude Science** planned and executed a search for a molecule capable of stabilizing the faulty enzyme responsible for **phenylketonuria**, screening **2,200 compounds** spread across **80 graphics processors**, before narrowing the selection to four promising candidates and producing a decision memo. The same **triage process** was then repeated simultaneously across roughly a hundred **rare diseases**. This demonstration, spectacular as it was, remains a **proof of concept** rather than a confirmed medical discovery: turning a computational candidate into an **approved treatment** still requires years of rigorous **clinical trials**, an essential reminder amid the current wave of technological enthusiasm. *I instinctively distrust overly polished demonstrations at product launches. Going from four molecular candidates to an actually approved drug remains a long, expensive, and obstacle-ridden path that artificial intelligence cannot magically shorten just yet.* ## The AI for Science grant program, an open door for independent researchers ### Up to fifty projects funded starting this year To broaden access to this technology, **Anthropic** announced a grant program supporting up to **50 research projects** around the world, each eligible for up to **30,000 dollars** in credits, with additional support of up to **2,000 dollars** in computing power provided by **Modal**. **Applications** remain open until **July 15, 2026**, with results expected to be announced on **July 31**, and **selected projects** will run from **September to December 2026**. This **tight timeline** reflects Anthropic's desire to demonstrate tangible results quickly. ### Access that is especially relevant for smaller university labs This program specifically targets university labs, nonprofit research institutes, and independent researchers who generally lack access to the massive computational resources of large pharmaceutical or technology companies. This **partial democratization** of access could reduce certain structural inequalities in the Western scientific research world. It remains to be seen whether this limited number of funded projects will be enough to generate a statistically significant impact, or whether it is more of a public relations exercise meant to polish Anthropic's image with the international scientific community. *I see this program as a commendable initiative, but a modest one given the scale of global scientific research needs. Fifty projects is an encouraging start, not a revolution, and it will be worth watching closely whether that number grows in the years ahead.* ## A technology race among Western artificial intelligence giants ### OpenAI and Google DeepMind are not standing still The launch of **Claude Science** puts **Anthropic** in direct competition with **OpenAI**, which is developing comparable tools reserved for enterprise clients, and **Google DeepMind**, whose proprietary scientific models already occupy an important place in some cutting-edge labs. This **rivalry** among American tech giants could considerably accelerate the pace of artificial-intelligence-assisted **scientific innovation**. This **competition** among Western companies, though commercially intense, carries a **collective strategic advantage**: it keeps the **West's** technological lead in a field where **China** is investing massively to close its perceived gap. ### Why Western technological supremacy remains a geopolitical stake It would be naive to view this development as purely commercial or scientific. The ability to dominate research at the intersection of artificial intelligence and the sciences is a matter of **national security** and long-term **economic competitiveness**, particularly given the technological ambitions displayed by **China** in biotechnology and artificial intelligence. Companies like **Anthropic**, **OpenAI**, and **Google DeepMind** play, whether they intend to or not, a role in preserving **Western technological leadership** against **strategic rivals** that do not share the same democratic values or the same ethical safeguards. *I firmly believe this technology race, imperfect and sometimes commercially cynical as it is, serves a broader geopolitical goal: preventing authoritarian regimes from gaining a decisive edge in technologies that will shape the twenty-first century.* ## Early users report notable efficiency gains ### Prestigious institutions among the first adopters Recognized organizations such as **Manifold Bio**, the **Allen Institute**, and the **University of California, San Francisco**, are among the early users who tested the platform in beta, reporting **efficiency gains of several orders of magnitude** on genomics tasks, drug target nomination, and long-form literature review. These **testimonials**, while encouraging, come from **partner sources** directly associated with the product launch, which calls for some **methodological caution** before accepting these figures as **independent, generalizable results**. ### Novo Nordisk, a partnership that underscores the pharmaceutical ambition Pharmaceutical giant **Novo Nordisk** is also among the case studies highlighted by **Anthropic**, suggesting that major pharmaceutical companies are already working simultaneously with several artificial intelligence providers to accelerate their own research and development processes. This **diversification of industrial partnerships** shows that the Western pharmaceutical industry is not betting everything on a single technology provider, a cautious approach that limits the risks of **excessive dependence** on any one artificial intelligence company. *I remain mindful that success stories cited by a company at the launch of its own product always deserve to be received with measured skepticism, even when they come from otherwise respected and serious institutions.* ## The limits and gray areas that should not be ignored ### A tool, not a guarantee of discovery Despite the enthusiasm surrounding this launch, **Claude Science** remains fundamentally a process-acceleration tool, not a guarantee of a revolutionary scientific discovery. An article published by **Entrelligence** rightly points out that this is an announcement of intent and a beta-stage tool, not a shelf stocked with new drugs ready to save lives. This **essential distinction** helps avoid **excessively optimistic media coverage** that would artificially inflate public expectations for a technology still in its early stages, whose **real impact on health** remains to be demonstrated over several years. ### The question of scientific institutions' technological dependence Another issue deserves reflection: as more labs and universities adopt tools like **Claude Science**, a form of technological dependence on a handful of private companies could become durably embedded in the global scientific research ecosystem, with implications for data control and intellectual property over discoveries. These **structural questions** deserve a **serious public debate**, beyond the immediate technological enthusiasm generated by each new product launch in this fast-moving sector. *I believe the scientific community must stay vigilant against this growing dependence on private tools, however useful they may be. Basic research should never become a hostage to the commercial interests of a handful of technology companies, however well-intentioned they may be.* ## What this means for the future of Western research ### A potential acceleration that could redefine scientific competitiveness If **Claude Science's** promises hold up at larger scale, the impact on the speed of Western scientific research could be considerable, letting researchers devote more time to the creative interpretation of results rather than the tedious management of disparate, incompatible tools. This acceleration, if it truly materializes, would strengthen the **West's** position in the global **innovation race**, a significant strategic advantage against rivals like **China**, which is investing massively in its own artificial-intelligence-for-science capabilities. ### A decisive test in the coming months The coming months, particularly with results from the **AI for Science** program expected in the fall of 2026, will show whether these initial promises translate into concrete, verifiable scientific advances, or remain impressive demonstrations with no tangible follow-through for society. This will be the real **credibility test** for **Anthropic**, whose long-term scientific reputation will directly depend on its ability to turn these technological promises into **measurable results** for patients and for science in general. *I will keep a close, cautiously optimistic eye on the concrete results of this technological bet. The history of artificial intelligence is full of spectacular promises that sometimes proved disappointing in practice, and scientific rigor must always come before marketing enthusiasm.* ## The legacy of Claude for Life Sciences, the October 2025 foundation ### A quiet first step toward today's scientific ambition To understand the scope of this launch, one must go back to **October 2025**, when **Anthropic** had already introduced **Claude for Life Sciences**, an initial suite of connectors and specialized skills that made the **Claude** chatbot more capable for everyday scientific tasks. **Claude Science** is therefore not a sudden break, but the logical culmination of a strategy set in motion months earlier. This **strategic continuity** reveals a company methodically building its presence in the **life sciences** sector, rather than betting on an isolated marketing stunt to grab media attention for a single announcement. ### A trajectory comparable to that of Claude Code for developers **Anthropic's** leaders themselves draw an explicit parallel with **Claude Code**, the tool that made the company an essential reference for software developers. The stated goal is to replicate that same success in the scientific domain, becoming the indispensable **operational layer** for researchers worldwide. This ambition, if it materializes, would transform **Anthropic** from a mere language model provider into an indispensable infrastructure for entire swaths of the Western knowledge economy, an extremely valuable strategic position over the long term. *I find it telling that Anthropic is explicitly trying to replicate its winning Claude Code formula in a completely different sector. That suggests a coherent corporate strategy rather than a string of improvised bets, which should reassure observers about how serious this effort is.* ## The technical infrastructure behind the scientific promise ### Flexible management of computing power **Claude Science** can manage computing power ranging from a single **graphics processor** to hundreds spread across laptops, high-performance computing clusters, and on-demand services like **Modal**. This technical flexibility addresses a real need for labs, whose computing resources vary enormously depending on their size and funding. Researchers can also maintain **persistent Python and R kernels**, a **technical detail** that, while understated, considerably reduces the everyday friction experienced by anyone who has juggled multiple incompatible **programming environments**. ### Integration with Nvidia's cutting-edge tools The platform also integrates the **NVIDIA BioNeMo Agent Toolkit**, providing access to specialized life sciences models such as **Evo 2**, **Boltz-2**, and **OpenFold3**. This collaboration among American tech giants illustrates how much the Western scientific artificial intelligence ecosystem now relies on cross-partnerships between complementary companies. This technical interoperability, rather than closed competition between rival technology silos, could constitute a lasting competitive advantage for the entire Western artificial-intelligence-for-science industry. *I see this interoperability between Anthropic and Nvidia as an encouraging sign. Rather than building closed, competing ecosystems, Western companies seem to understand that a degree of technical collaboration better serves their collective interests against foreign rivals.* ## Reactions from the international scientific community ### A broadly positive but measured reception International media coverage of this launch has been largely positive, with several specialized publications highlighting the tool's real potential to reduce the administrative and technical friction that traditionally slows down scientific research. This **favorable reception** contrasts with the more pronounced **skepticism** that often accompanies artificial intelligence announcements in other sectors. This contrast is partly explained by the very nature of the product: unlike generalist tools sometimes perceived as threatening to employment, **Claude Science** presents itself explicitly as an assistance tool for highly skilled professionals, rather than as a substitute for their expertise. ### Critical voices call for methodological caution Some independent researchers nonetheless point out that the rapid adoption of artificial intelligence tools in scientific research must come with strict methodological standards to prevent the scientific literature from being contaminated by insufficiently verified results. This concern, while legitimate, should not overshadow the real benefits these tools can bring when used responsibly. Striking the balance between rapid innovation and scientific rigor remains the central challenge of this new era, a balance that neither **Anthropic** nor any other tech company can guarantee alone, without the active involvement of scientific institutions themselves. *I believe this balance between innovation and rigor can only be achieved through collective vigilance, including scientific journals, universities, and public funding agencies, rather than relying solely on the goodwill of the private companies commercializing these tools.* ## The potential impact on rare and neglected diseases ### A market traditionally abandoned by the pharmaceutical industry **Neglected diseases** and **rare diseases** historically suffer from chronic underinvestment by the traditional pharmaceutical industry, for lack of a market lucrative enough to justify the enormous costs of developing new treatments. This is precisely the gap **Anthropic's** drug discovery program claims it wants to fill. If this promise materializes, even partially, it could offer **tangible hope** to patient populations long ignored by the classic mechanisms of **pharmaceutical development**, a morally commendable goal regardless of the company's underlying commercial motives. ### A particular responsibility for a company with a social mission **Anthropic** presents itself as a **public benefit corporation**, a legal status that in theory allows it to prioritize the social benefit of its projects over immediate commercial profitability alone. This particular legal structure partly justifies its entry into a field as unprofitable as neglected diseases. It remains to be seen whether this statutory promise will translate into sustained long-term investment, or whether it will remain a convenient public-relations statement of intent without a financial commitment proportionate over time. *I want to believe in the sincerity of this commitment to neglected diseases, but I will keep watching the budgets actually allocated in the years ahead. The good intentions on display at a media launch are only worth something if they translate into concrete, sustained investment.* ## The still-uncertain regulatory context around scientific AI ### A legal vacuum that worries some experts The rapid rise of tools like **Claude Science** comes amid a regulatory context that remains largely incomplete in the **West**, where few legal frameworks specifically exist to govern the use of artificial intelligence in drug discovery or sensitive biomedical research. This **lack of specific regulation** creates a **gray zone** that tech companies are quickly occupying, sometimes before lawmakers can even react. In the **United States** as in the **European Union**, regulatory discussions on artificial intelligence are progressing, but often remain focused on general issues rather than specific life sciences applications, a lag that could become problematic as these tools gain in power and autonomy. ### Why Anthropic's self-regulation is not enough on its own **Anthropic** insists that **Claude Science** is built on models that have undergone its standard safety and biosecurity evaluations. These internal safeguards, reassuring as they may sound on paper, do not replace independent regulatory oversight that would hold the company externally accountable for any potential missteps. This question of independent governance will likely become central as these tools take on a growing role in fields as sensitive as pharmaceutical research and synthetic biology, where the consequences of an error or an abuse could be considerable. *I believe Western governments have fallen worryingly behind on regulating artificial intelligence applied to the life sciences. A company's stated good faith, however sincere, cannot replace independent, binding public oversight.* ## Why this announcement fits Anthropic's long-term strategy ### Diversifying revenue beyond consumer subscriptions By moving into the life sciences market, **Anthropic** is strategically diversifying its revenue sources beyond simple consumer subscriptions to **Claude Pro** and **Claude Max**. **Institutional contracts** with pharmaceutical giants and universities represent a **potentially more stable** and lucrative long-term market than fierce competition alone in the consumer conversational-assistant market. This diversification fits a prudent business logic for a company valued at tens of billions of dollars, which must demonstrate to its investors an ability to generate durable revenue beyond the initial hype for conversational **chatbots**. ### A bet on long-term loyalty from scientific institutions By becoming indispensable to researchers' daily workflows, **Anthropic** is banking on lasting **institutional loyalty**, harder to break than a simple individual subscription cancelable in a few clicks. This lock-in strategy, common in the tech industry, could prove especially effective in a sector as conservative and methodical as institutional scientific research. It remains to be seen whether this clever business strategy will truly serve the long-term interests of open science, or whether it will instead reinforce a problematic structural dependence on a single, private technology provider. *I remain torn between admiration for Anthropic's strategic savvy and concern over the growing concentration of scientific technological power in the hands of a few American private companies, however well-intentioned they may be at this stage.* ## Conclusion: a technological bet with stakes beyond science alone ### Real progress, but bounded by very real limits This analysis confirms that **Claude Science** represents a significant technological development, potentially capable of accelerating certain aspects of everyday scientific work, without constituting an instant revolution or a guarantee of immediate medical discoveries for patients suffering from neglected diseases. The **methodological caution** built into the tool, notably through the **reviewer agent** and the **auditable history** of results, is a responsible response to legitimate fears surrounding the use of artificial intelligence in scientific research. ### A stake that goes far beyond the technological framework alone Beyond the technical feat, this launch fits into a broader geopolitical competition for global technological supremacy, where the **West**, through companies like **Anthropic**, **OpenAI**, and **Google DeepMind**, seeks to maintain its lead against strategic rivals that do not necessarily share the same democratic values. It is this geopolitical dimension, often overlooked in technology media coverage, that gives this announcement an importance extending far beyond the narrow circle of researchers and university labs directly involved. *I end this analysis with one conviction: the real technological battle of the twenty-first century will not be fought only in microchips or language models, but in the ability to turn these tools into concrete discoveries that improve real human lives.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - Anthropic, official announcement of Claude Science — June 30, 2026 - Anthropic, official company announcements page - Reuters, Anthropic unveils Claude Science artificial intelligence platform for scientific research — June 30, 2026 ### Secondary sources - TechCrunch, Claude Science bets on workflow rather than a new model — June 30, 2026 - CNBC, Anthropic launches AI drug discovery program with Claude Science — June 30, 2026 - Forbes, Anthropic's new AI workbench put to the test — June 30, 2026 - Let's Data Science, Anthropic launches Claude Science and its drug program — July 2, 2026 --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/claude-science-l-outil-qui-pourrait-accelerer-la-recherche-scientifique-occident